

26th March 2007

Topical Issues with Drug Eluting Stents
Roundtable Meeting Monday 26th March 2007, 12.00 – 2.00pm
Lafourche Room, Loews Hotel, New Orleans, USA

Co-chairs: Steven Steinhubl, USA and Sigmund Silber, Germany

12.00 – 12.30pm	Lunch	
12.30 – 12.35pm	Introduction	<i>Co-chairs</i>
12.35 – 12.55pm	Drug Eluting Stents (DES): Review of the ongoing debate	<i>J. Popma</i>
12.55 – 1.25pm	Group Discussion:	<i>All</i>
	Impact on DES utilization	
	<ul style="list-style-type: none">• What impact has been felt in clinical practice patterns on the use of DES in the US?• Are DES being used more selectively now? And if so, in what types of patients?• Is there an increase in use of Bare Metal Stents (BMS) as a result of these issues?• What is the impact on DES use in Europe?	
1.25 – 1.55pm	Impact on prescribing patterns and the use of antiplatelet therapies in patients receiving DES	<i>All</i>
	<ul style="list-style-type: none">• Is late stent thrombosis perceived as an antiplatelet therapy issue or a DES issue?• Dual antiplatelet therapy after DES: what is the optimal duration of therapy?• In which patients should dual antiplatelet therapy be extended beyond 12 months?	
	Potential Additional Questions:	
	<ul style="list-style-type: none">• Should tests for drug responsiveness be used? Which ones, when, and, in which patients?• What antiplatelet therapy should be considered in PAD patients with DES after 12 months?	
1.55 – 2.00pm	Concluding Remarks	<i>Co-chairs</i>